This document discusses the potential benefits of sacubitril/valsartan (Entresto) treatment for COVID-19 patients. It notes that SARS-CoV-2 binds to ACE2 receptors, leading to ACE2 downregulation and increased lung pathology. However, ARBs like valsartan may protect the lungs by upregulating ACE2 expression and blocking the renin-angiotensin system. Sacubitril inhibits neprilysin and increases levels of peptides that have anti-inflammatory effects. Studies show sacubitril/valsartan reduces inflammation markers and increases lymphocytes more than valsartan alone. Based on these mechanisms, the authors suggest early administration of sacubitril/vals